Try our beta test site
46 studies found for:    Annexin
Show Display Options
Rank Status Study
1 Withdrawn Effect of Ischemic Postconditioning on Targeting of Annexin A5 After Forearm Exercise
Conditions: Cardiovascular Disease;   Ischemia-reperfusion Injury;   Postconditioning
Intervention: Procedure: repetitive short ischemia and reperfusion of non dominant fore arm after 10 minute ischemic exercise
2 Completed Annexin A2 as a Novel Diagnostic Marker in Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma (HCC)
Intervention: Procedure: blood sample
3 Not yet recruiting Detection of Annexin A2 in Systemic Lupus Erythematosus
Conditions: Systemic Lupus Erythematosus (SLE);   Lupus Nephritis
Intervention: Other: ANXA2
4 Completed Study the Expression of Annexin A1 and Its Potential Usage as a Prognostic Marker in Oral Cancer
Condition: Squamous Cell Carcinoma
Intervention:
5 Completed The Effect of Rosiglitazone on Ischemia-reperfusion-injury Using Annexin A5 Scintigraphy.
Conditions: Ischemia-Reperfusion Injury;   The Metabolic Syndrome
Intervention: Drug: rosiglitazone
6 Recruiting Assessment of Radiolabeled rhAnnexin V-128 in Infective Endocarditis
Conditions: Endocarditis;   Thrombosis
Intervention: Other: 99mTc-Annexin V-128 SPECT
7 Unknown  Annexin A3 (ANXA3) as Protein-Based Marker for Non-Invasive Molecular Diagnostics of Prostate Carcinoma
Conditions: Prostate Cancer;   Benign Prostatic Hyperplasia;   Prostatic Intraepithelial Neoplasia
Intervention:
8 Recruiting Serum Caspase 3, Annexin a2 and Soluble Fas Levels and Endometriosis
Conditions: Endometriosis;   Apoptotic Pathway Deregulation
Intervention: Other: Blood sample
9 Completed The Influence of the 34C>T Variant in the AMPD1 Gene Ischemic Tolerance
Conditions: AMPD;   Ischemic Tolerance
Interventions: Drug: systemic administration of 99mTc-HYNIC-Annexin A5;   Behavioral: 10 minutes of ischemic handgripping
10 Unknown  Effect of HCQ on AnxA5 Resistance Assay in Antiphospholipid (aPL) Positive Patients With and Without Systemic Lupus Erythematosus (SLE)
Conditions: Antiphospholipid Syndrome;   Thrombophilia Due to Antiphospholipid Antibody;   Systemic Lupus Erythematosus
Intervention: Other: Phlebotomy
11 Completed Rosuvastatin and Ischemia Reperfusion
Condition: Ischemia
Intervention: Drug: Rosuvastatin
12 Completed The Effect of Caffeine on Ischemic Preconditioning
Conditions: Caffeine;   Ischemic Preconditioning;   Ischemia-Reperfusion Injury
Interventions: Drug: caffeine;   Drug: Technetium-TC99m-labeled Annexin A5;   Procedure: ten minutes forearm ischemia;   Procedure: ischemic forearm exercise
13 Suspended Opioid Receptors Influence Ischemia-Reperfusion Injury
Condition: Ischemia-Reperfusion Injury
Interventions: Drug: morphine;   Drug: naloxone;   Drug: Technetium-TC99m-labeled Annexin A5;   Procedure: forearm ischemic exercise;   Procedure: ten minute forearm ischemia
14 Completed Does Atorvastatin Reduce Ischemia-Reperfusion Injury in Humans in-Vivo?
Conditions: Ischemia Reperfusion Injury;   Cardiovascular Disease
Intervention: Drug: atorvastatin
15 Completed Ischemic Injury and Ischemic Preconditioning in Diabetes
Conditions: Diabetes Mellitus, Insulin-Dependent;   Ischemia-Reperfusion Injury
Interventions: Procedure: Ischemic preconditioning;   Procedure: Forearm ischemic exercise;   Procedure: Annexin A5 scintigraphy;   Drug: Diazoxide;   Drug: glibenclamide;   Drug: adenosine
16 Unknown  Infusion of a Single Dose of Erythropoietin to Prevent Injury in an Ischemia Reperfusion Forearm Model
Conditions: Ischemia-Reperfusion Injury;   Myocardial Infarction
Interventions: Drug: Epoetin alpha;   Drug: NaCl
17 Completed Does Caffeine Reduce Dipyridamole-Induced Protection Against Ischemia-Reperfusion Injury?
Conditions: Cardiovascular Disease;   Ischemia-Reperfusion Injury
Interventions: Drug: Dipyridamole;   Drug: caffeine
18 Completed Does Caffeine Reduce Rosuvastatin-Induced Protection Against Ischemia-Reperfusion Injury?
Condition: Ischemia Reperfusion Injury
Intervention: Drug: Rosuvastatin
19 Completed Short Term Statin Treatment and Endothelial Dysfunction Due to Ischemia and Reperfusion Injury
Conditions: Ischemia Reperfusion Injury;   Endothelial Dysfunction
Interventions: Drug: rosuvastatin;   Drug: atorvastatin 3 days;   Drug: placebo;   Drug: rosuvastatin 7 days;   Drug: atorvastatin 7 days;   Drug: placebo 7 days
20 Active, not recruiting DCE-MRI PET Bevacizumab Study in Rectal Cancer
Condition: Rectal Cancer Patients
Intervention: Drug: Bevacizumab 5 mg/kg

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.